Pub Date : 2019-01-01DOI: 10.4172/2165-7920.10001216
K. Murayama, K. Oinuma, T. Tamaki
Bone cement which can reach temperatures of >100°C, is commonly used to fix the femoral stem in total hip arthroplasty (THA). However, reports on skin burns due to bone cement are rare. The primary purpose of this article is to report these rare cases to prevent these complications. Two cases were simultaneous bilateral THA (case A and B) and two cases were unilateral THA (case C and D) are discussed in this case report. In these cases, the maximum thickness of excessive bone cement was >10 mm.
{"title":"Cement Burn of the Skin During Total Hip Arthroplasty: A Case Series","authors":"K. Murayama, K. Oinuma, T. Tamaki","doi":"10.4172/2165-7920.10001216","DOIUrl":"https://doi.org/10.4172/2165-7920.10001216","url":null,"abstract":"Bone cement which can reach temperatures of >100°C, is commonly used to fix the femoral stem in total hip arthroplasty (THA). However, reports on skin burns due to bone cement are rare. The primary purpose of this article is to report these rare cases to prevent these complications. Two cases were simultaneous bilateral THA (case A and B) and two cases were unilateral THA (case C and D) are discussed in this case report. In these cases, the maximum thickness of excessive bone cement was >10 mm.","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2165-7920.10001216","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70707839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.4172/2165-7920.10001202
A. Abdel-Gadir
Surgicel is oxidized regenerated cellulose used successfully for haemostasis and prevention of adhesions for many years in different surgical disciplines. However, many reports of different related complications appeared in the literature. In this manuscript I am reporting on two patients who had surgicel gauze removed from the pelvis many months after surgery because of intolerable dull pelvic pain and intermittent low-grade fever. Transvaginal ultrasound scan examinations in both cases showed tubular masses with medium echogenicity in the pelvis which were mistaken for dilated fallopian tubes. Both patients responded well after laparoscopic surgicel removal and pelvic lavage with 2 litres of warm normal saline. This was followed by instillation of 500 mg of hydrocortisone diluted in 50 ml of saline. Culture of the peritoneal contents was negative. In both cases the symptoms were mostly related to foreign body reaction as the gauze was isolated and encapsulated within a thin membrane. Furthermore, neither patient needed any antibiotics after it was removed. These are the first two case reports for retained surgicel used during laparoscopic gynaecological surgery to be mistaken for dilated fallopian tubes. I suggest that all patients who had surgicel used during similar operations should have transvaginal ultrasound scan examination one month after the procedure, or even sooner if they remained symptomatic. Any tubular pelvic mass should be explored by diagnostic laparoscopy as it might be a retained surgicel gauze. Better still, a clinical preoperative test needs to be developed to check which patients might be at risk of developing such complications.
{"title":"Retained Pelvic Oxidized Regenerated Cellulose Mistaken for Dilated Fallopian Tubes","authors":"A. Abdel-Gadir","doi":"10.4172/2165-7920.10001202","DOIUrl":"https://doi.org/10.4172/2165-7920.10001202","url":null,"abstract":"Surgicel is oxidized regenerated cellulose used successfully for haemostasis and prevention of adhesions for many years in different surgical disciplines. However, many reports of different related complications appeared in the literature. In this manuscript I am reporting on two patients who had surgicel gauze removed from the pelvis many months after surgery because of intolerable dull pelvic pain and intermittent low-grade fever. Transvaginal ultrasound scan examinations in both cases showed tubular masses with medium echogenicity in the pelvis which were mistaken for dilated fallopian tubes. Both patients responded well after laparoscopic surgicel removal and pelvic lavage with 2 litres of warm normal saline. This was followed by instillation of 500 mg of hydrocortisone diluted in 50 ml of saline. Culture of the peritoneal contents was negative. In both cases the symptoms were mostly related to foreign body reaction as the gauze was isolated and encapsulated within a thin membrane. Furthermore, neither patient needed any antibiotics after it was removed. These are the first two case reports for retained surgicel used during laparoscopic gynaecological surgery to be mistaken for dilated fallopian tubes. I suggest that all patients who had surgicel used during similar operations should have transvaginal ultrasound scan examination one month after the procedure, or even sooner if they remained symptomatic. Any tubular pelvic mass should be explored by diagnostic laparoscopy as it might be a retained surgicel gauze. Better still, a clinical preoperative test needs to be developed to check which patients might be at risk of developing such complications.","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2165-7920.10001202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70706326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.4172/2165-7920.10001210
Alqahatni Yam
{"title":"A Rare Chromosome 18p Deletion Syndrome in Abha City: A Case Study","authors":"Alqahatni Yam","doi":"10.4172/2165-7920.10001210","DOIUrl":"https://doi.org/10.4172/2165-7920.10001210","url":null,"abstract":"","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2165-7920.10001210","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70707353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.4172/2165-7920.10001200
Ning Y, Yan X, Xie D, J. G
Objective: Inflammatory myofibroblastic tumor is a very rare mesenchymal tumor, we share our experience of surgical treatment for inflammatory myofibroblastic tumor. Materials and Methods: From January 2005 to January 2015, 32 patients were recruited in this study including 13 males and 19 females who received surgery and diagnosed as inflammatory myofibroblastic tumor. Postoperative followup was conducted by thoracic surgeons every 3 months until 12 months after surgery, after that every 6 months until 24 months, and then yearly. Results: 32 patients (aged: 9-72 yr, average:37.85 ± 19.42 yr, 13 males and 19 females ) received surgical treatment for inflammatory myofibroblastic tumor (ranged:0.8-8 cm, average:3.84 ± 2.05 cm), including 15 cases of lobectomy, 7 cases of wedge resection, 4 cases of bronchoplasty, 2 case of tracheal tumor resection, 3 cases of sleeve resection and 1 case of wedge resection with biopsy of the chest wall. 31 patients are still alive till now, while one patient die 6 months after the surgery. Conclusion: It suggested that complete resection of the IMT lesions may lead to a promising long-term survival, otherwise it may lead to a compromised outcome.
{"title":"Pulmonary Inflammatory Myofibroblastic Tumor: Surgical Resection and Long-Term Surveillance","authors":"Ning Y, Yan X, Xie D, J. G","doi":"10.4172/2165-7920.10001200","DOIUrl":"https://doi.org/10.4172/2165-7920.10001200","url":null,"abstract":"Objective: Inflammatory myofibroblastic tumor is a very rare mesenchymal tumor, we share our experience of surgical treatment for inflammatory myofibroblastic tumor. Materials and Methods: From January 2005 to January 2015, 32 patients were recruited in this study including 13 males and 19 females who received surgery and diagnosed as inflammatory myofibroblastic tumor. Postoperative followup was conducted by thoracic surgeons every 3 months until 12 months after surgery, after that every 6 months until 24 months, and then yearly. Results: 32 patients (aged: 9-72 yr, average:37.85 ± 19.42 yr, 13 males and 19 females ) received surgical treatment for inflammatory myofibroblastic tumor (ranged:0.8-8 cm, average:3.84 ± 2.05 cm), including 15 cases of lobectomy, 7 cases of wedge resection, 4 cases of bronchoplasty, 2 case of tracheal tumor resection, 3 cases of sleeve resection and 1 case of wedge resection with biopsy of the chest wall. 31 patients are still alive till now, while one patient die 6 months after the surgery. Conclusion: It suggested that complete resection of the IMT lesions may lead to a promising long-term survival, otherwise it may lead to a compromised outcome.","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2165-7920.10001200","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70706502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.4172/2165-7920.10001226
Swarupa Kb, Anupama Tadepalli, Harinath Parthasarathy, D. Ponnaiyan
Background: Various biomaterials have been employed along with Coronally advanced flap (CAF) in root coverage procedures. The combined efficacy of bioactive glass and Platelet rich fibrin in management of gingival recession needs to be evaluated. Aim: The aim of the present study was to clinically evaluate the efficacy of bioactive glass putty, platelet rich fibrin (PRF) and a combination of both in management of maxillary gingival recession defects. Materials and methods: 31 patients with 60 Millers class I/II recession defects were treated with one of the following interventions; GROUP I: CAF alone, GROUP II, III and IV: CAF+Bioactive glass, CAF+PRF,CAF+ Bioactive glass+PRF respectively Clinical parameters such as recession height (RH), recession width (RW), probing pocket depth (PPD), clinical attachment level (CAL), width of attached gingiva (WAG),keratinized tissue height (KTH) were evaluated at baseline for 6 months. Mean root coverage (RC%), changes in biotype, RES and VAS aesthetic scores evaluated at the end of 6 months intervals. Results: RH and RW showed statistically significant reduction from baseline to 6 months in all the groups (p ≤ 0.05). At the end of 6 months, the mean RC% was 61.0% ± 34.3%, 75.5% ± 25.9%, 67.2% ± 32.8% and 81.7% ± 28.6% in Group I, II, III and IV respectively. Intergroup analysis showed no statistically significant difference of parameters between groups at any time point. Conclusion: All the therapeutic interventions were effective in management of gingival recession defects. Though, group IV showed greater mRC% when compared to other groups, intergroup analysis failed to show any statistical significance.
{"title":"Clinical Efficacy of Bioactive Glass in Combination with Platelet Rich Fibrin in Management of Gingival Recession Defects: A Prospective Comparative Study","authors":"Swarupa Kb, Anupama Tadepalli, Harinath Parthasarathy, D. Ponnaiyan","doi":"10.4172/2165-7920.10001226","DOIUrl":"https://doi.org/10.4172/2165-7920.10001226","url":null,"abstract":"Background: Various biomaterials have been employed along with Coronally advanced flap (CAF) in root coverage procedures. The combined efficacy of bioactive glass and Platelet rich fibrin in management of gingival recession needs to be evaluated. Aim: The aim of the present study was to clinically evaluate the efficacy of bioactive glass putty, platelet rich fibrin (PRF) and a combination of both in management of maxillary gingival recession defects. Materials and methods: 31 patients with 60 Millers class I/II recession defects were treated with one of the following interventions; GROUP I: CAF alone, GROUP II, III and IV: CAF+Bioactive glass, CAF+PRF,CAF+ Bioactive glass+PRF respectively Clinical parameters such as recession height (RH), recession width (RW), probing pocket depth (PPD), clinical attachment level (CAL), width of attached gingiva (WAG),keratinized tissue height (KTH) were evaluated at baseline for 6 months. Mean root coverage (RC%), changes in biotype, RES and VAS aesthetic scores evaluated at the end of 6 months intervals. Results: RH and RW showed statistically significant reduction from baseline to 6 months in all the groups (p ≤ 0.05). At the end of 6 months, the mean RC% was 61.0% ± 34.3%, 75.5% ± 25.9%, 67.2% ± 32.8% and 81.7% ± 28.6% in Group I, II, III and IV respectively. Intergroup analysis showed no statistically significant difference of parameters between groups at any time point. Conclusion: All the therapeutic interventions were effective in management of gingival recession defects. Though, group IV showed greater mRC% when compared to other groups, intergroup analysis failed to show any statistical significance.","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2165-7920.10001226","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70708898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.4172/2165-7920.10001219
B. M, Pazdirek F, K. T., H. J.
{"title":"How a Few Centimetres can Make all the Difference: An Unusual Treatment for Recurrent Postoperative Cholangitis in a Patient with a Biliary-Enteric Anastomosis","authors":"B. M, Pazdirek F, K. T., H. J.","doi":"10.4172/2165-7920.10001219","DOIUrl":"https://doi.org/10.4172/2165-7920.10001219","url":null,"abstract":"","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2165-7920.10001219","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70708127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.4172/2165-7920.10001209
Hashim R, Hamzah H, Zain Mn, Hadi Zla, Francis Al
{"title":"Performance Comparison of Francis Media with Other Methods in the Identification of Burkholderia pseudomallei","authors":"Hashim R, Hamzah H, Zain Mn, Hadi Zla, Francis Al","doi":"10.4172/2165-7920.10001209","DOIUrl":"https://doi.org/10.4172/2165-7920.10001209","url":null,"abstract":"","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2165-7920.10001209","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70707367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-01DOI: 10.4172/2165-7920-c2-019
D. Kopsky, J. Hesselink
{"title":"From case-series to a placebo-controlled n-of-1 clinical trial of topical analgesics in the treatment of peripheral neuropathic pain: How to enhance the level of evidence of a case-report?","authors":"D. Kopsky, J. Hesselink","doi":"10.4172/2165-7920-c2-019","DOIUrl":"https://doi.org/10.4172/2165-7920-c2-019","url":null,"abstract":"","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47748974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-01DOI: 10.4172/2165-7920-C2-020
pBelkina Natalia NRyzhova Nk Pasina Ob, Zakharova EAp
{"title":"A clinical case of prolonged primary infertility in a context of multiple uterine fibroids of a giant size","authors":"pBelkina Natalia NRyzhova Nk Pasina Ob, Zakharova EAp","doi":"10.4172/2165-7920-C2-020","DOIUrl":"https://doi.org/10.4172/2165-7920-C2-020","url":null,"abstract":"","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70752431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-29DOI: 10.4172/2165-7920.10001183
R. Jc, Park Ch, Choi Hj, Y. Kim
Although autologous adipose stem cells have much therapeutic potential for incurable diseases, safety concerns have been constantly raised for clinical use. An intrathecal injection of the stem cells to improve therapeutic efficiency in central nervous system diseases is also reluctant due to concerns of adverse reaction. To investigate the safety of multiple intrathecal administrations of autologous adipose-derived mesenchymal stem cells (hAdMSCs), adverse reactions were analyzed by questionnaire survey and blood chemistry examination in 70 patients with Parkinson’s disease and other neurodegenerative diseases who received hAdMSCs multiple times in China and Japan, retrospectively. As results, multiple IT administrations of cultured autologous hAdMSCs were safe, although mild back pain at the injection site in 4 patients and headache, dizziness, fever and asleep legs in other 4 patients. Adverse reactions were disappeared completely without specific treatment within a day. There were no serious adverse reactions during the cell treatment period. No remarkable atypical clinical change was observed in the blood analysis before and after the cell administrations. This study demonstrates that multiple IT administrations of hAdMSCs are safe for clinical use.
{"title":"Safety of Multiple Intrathecal Administrations of Cultured Human Autologous Adipose-Derived Stem Cells in the Patients with Neurological Disorders Including Parkinson’s Disease","authors":"R. Jc, Park Ch, Choi Hj, Y. Kim","doi":"10.4172/2165-7920.10001183","DOIUrl":"https://doi.org/10.4172/2165-7920.10001183","url":null,"abstract":"Although autologous adipose stem cells have much therapeutic potential for incurable diseases, safety concerns have been constantly raised for clinical use. An intrathecal injection of the stem cells to improve therapeutic efficiency in central nervous system diseases is also reluctant due to concerns of adverse reaction. To investigate the safety of multiple intrathecal administrations of autologous adipose-derived mesenchymal stem cells (hAdMSCs), adverse reactions were analyzed by questionnaire survey and blood chemistry examination in 70 patients with Parkinson’s disease and other neurodegenerative diseases who received hAdMSCs multiple times in China and Japan, retrospectively. As results, multiple IT administrations of cultured autologous hAdMSCs were safe, although mild back pain at the injection site in 4 patients and headache, dizziness, fever and asleep legs in other 4 patients. Adverse reactions were disappeared completely without specific treatment within a day. There were no serious adverse reactions during the cell treatment period. No remarkable atypical clinical change was observed in the blood analysis before and after the cell administrations. This study demonstrates that multiple IT administrations of hAdMSCs are safe for clinical use.","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2165-7920.10001183","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41463886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：